

Recombinant SARS-CoV-2 (Omicron, B.1.1.529) Spike RBD protein (G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H), C-His (HEK293)

Catalog Number: bs-43078P

Concentration: >0.5 mg/ml

AA Seq: 319-537/1273

Predicted MW: 26.9

Detected MW: 36 kDa

Tags: C-His

Activity: Not tested

Endotoxin: Not analyzed

Purity: >90% as determined by SDS-PAGE

Purification: AC


Form: Lyophilized or Liquid

Storage: PBS (pH7.4).

Stored at -70°C or -20°C. Avoid repeated freeze/thaw cycles.

Background: The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct.

VALIDATION IMAGES



Measured by its binding ability in a functional ELISA.

Immobilized human ACE2, His-Avi Tag (Cat: bs-46001P) at 2µg/mL (100 µL/Well) can bind SARS-CoV-2 Spike RBD (G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H), His Tag (Cat: bs-43078P), the EC50 is 187ng/mL.



The purity of the protein is greater than 90% as determined by reducing SDS-PAGE.